NovoCure Limited
NVCR
$11.13
-$0.55-4.71%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 167.20M | 158.81M | 154.99M | 161.27M | 155.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 167.20M | 158.81M | 154.99M | 161.27M | 155.10M |
| Cost of Revenue | 44.73M | 41.47M | 38.52M | 32.51M | 35.37M |
| Gross Profit | 122.48M | 117.33M | 116.47M | 128.75M | 119.72M |
| SG&A Expenses | 104.47M | 101.02M | 100.56M | 139.89M | 99.93M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 203.23M | 198.33M | 192.86M | 223.62M | 187.19M |
| Operating Income | -36.02M | -39.52M | -37.87M | -62.35M | -32.09M |
| Income Before Tax | -30.02M | -34.98M | -30.30M | -55.21M | -21.59M |
| Income Tax Expenses | 7.25M | 5.16M | 4.02M | 10.72M | 8.99M |
| Earnings from Continuing Operations | -37.27M | -40.14M | -34.32M | -65.92M | -30.57M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.27M | -40.14M | -34.32M | -65.92M | -30.57M |
| EBIT | -36.02M | -39.52M | -37.87M | -62.35M | -32.09M |
| EBITDA | -32.36M | -36.08M | -34.54M | -60.62M | -29.63M |
| EPS Basic | -0.33 | -0.36 | -0.31 | -0.61 | -0.28 |
| Normalized Basic EPS | -0.17 | -0.20 | -0.17 | -0.47 | -0.12 |
| EPS Diluted | -0.33 | -0.36 | -0.31 | -0.61 | -0.28 |
| Normalized Diluted EPS | -0.17 | -0.20 | -0.17 | -0.47 | -0.12 |
| Average Basic Shares Outstanding | 111.91M | 111.57M | 110.28M | 108.47M | 108.25M |
| Average Diluted Shares Outstanding | 111.91M | 111.57M | 110.28M | 108.47M | 108.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |